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ABSTRACT- 
Liposomes are colloidal particles formed as concentric bimolecular layers that are capable of 
encapsulating drugs. Liposomes have the potential for extending the duration of action for days or 
months. Tolnaftate  is is used as the topical antifungal agent.  The purpose ofthis study was to provide the 
delivery of the topical drug at a sustained rate across intact skin to improve bioavailability.  In present 
study, four different liposomes  formulations of Tolnaftate were prepared by ethanol (solvent) injection 
method by varying the concentrations of phospholipids.. The prepared liposomes were characterized for  
size, shape, entrapment efficiency, zeta potential, in-vitro drug release. An in vitro drug release of about 
82.114 % in 10 h was observed from optimum formulation of batch LS4. 
Key words: Tolnaftate, liposomes, phospholipid, entrapment efficiency,zeta potential, in-vitro drug 
release. 
 
INTRODUCTION: 
At present scenario liposome technology is one of the fastest growing scientific field 
contributing to different types of areas such as drug delivery, cosmetics, nanotechhnology etc
1
.  
The name liposome is derived from two Greek words: 'Lipos' meaning fat and 'Soma' meaning 
body. Liposomes are concentric bleeder vesicles containing aqueous volume entirely enclosed by 
a membraneous lipid bilayer
2
. These membranes are usually made of phospholipids, which are 
molecules that have a hydrophilic head group and a hydrophobictail group. The head is attracted 
to water, while the tail, is made of a long hydrocarbon chain, is repelled by water. Liposomes can 
be filled with drugs to for the treatment of different diseases
3
. 
Liposomes contains several advantageous characteristics such as ability to incorporate not only 
water soluble but also lipid soluble agents, specific targeting to the required site in the body and 
versatility in terms of fluidity, size, charge and number of lamellae. 
Cholesterol is added to impart different properties like increasing micro viscosity of the bilayer, 
reducing permeability of the membrane to water soluble molecules, stabilizing the membrane 
and increasing rigidity of the vesicle
4
. 
Tolnaftate  is a synthetic thio carbamate that is used as the topical antifungal agent. It inhibits the 
squalene epoxidase enzyme
5
. It is used in the treatmentof fungal conditions such as jock itch, 
athlete's foot and ringworm. Tolnaftate is only active by topical application and inactive when 
used  via oral and intraperitoneal routes
6
.  
Preparation of liposomes  
Tolnaftate liposomes were prepared by ethanol (solvent) injection method. The lipid, cholesterol, 
stearic acid and lipid soluble component, drug (25 mg) were dissolve in ethanol and injected in 
to 10 ml preheated distilled water at 55
0 
- 65
o
C with continuousstirring at 500 rpm using 
magnetic stirrer. The solvent was evaporated by heating so as to obtain drug loaded liposomes
7
. 
 
 
 
 
 
 
 Table 1: Composition of Tolnaftate liposomes 
Formulation 
code 
Phospholipid 
(mg) 
Cholesterol 
(mg) 
Sodium 
alginate (ml) 
Calcium 
chloride (ml) 
Stearic acid 
(mg) 
LS1 60 40 10 25 10 
LS2 50 50 10 25 10 
LS3 40 40 10 25 10 
LS4 30 50 10 25 10 
 
CHARECTERIZATION OF LIPOSOMES:  
Particle size analysis and surface morphology
8, 9 
The particle size of Tolnaftate liposomes was determined by optical microscopy. All the 
prepared batches of Liposome’s were viewed under microscope to study their size. Size of 
liposomal vesicles was measured at different location on slide bytaking a small drop of liposomal 
dispersion on it and average size of liposomal vesicles were determined. The surface 
morphology was studied by scanning electron microscopy. 
Measurement of Zeta potential
10, 11 
Zeta potential of the liposomes was measured using electrophoretic light scattering by a 
Malvern Zetasizer Nano ZS. The measurement was performed at 25°C afterappropriate 
dilution with distilled water. All of the measurements were repeated three times. 
Drug entrapment efficiency of liposomes
12, 13
  
Entrapment efficiency of Tolnaftate liposomes was determined by centrifugation method. 
Aliquots (1 ml) of liposomal dispersion were subjected to centrifugation on a laboratory 
centrifuge at 3500 rpm for a period of 90 min. The clear supernatants wereremoved carefully to 
separate non-entrapped Tolnaftate and absorbance recorded at 256 nm. 
 
 
In in-vitro drug release study
14, 15 
The release studies were carried out in diffusion cell having 10 ml capacity. 10 ml phosphate 
buffer pH 7.4 was placed in diffusion cell. The diffusion cell contained a magnetic bed and the 
medium was equilibrated at 37±5
0
C. Dialysis membrane was takenand placed on the diffusion 
cell. After separation of non-entrapped Tolnaftate liposomes dispersion was filled in the dialysis 
membrane. The dialysis membrane containing the sample was suspended in the medium. 
Aliquots were withdrawn (1 ml) at specific intervals, filtered, diluted with phosphate buffer and 
the absorbance was taken at 256 nm. Then the apparatus was immediately replenished with same 
quantity of fresh phosphate buffer pH 7.4 medium. 
Table 2: Evaluation parameters of  Tolnaftate liposomes 
Formulation code Zeta potential (mV) Vesicle size (nm) % Entrapment 
efficiency 
LS1 -18.4 ±0.87 325.83 ±0.15 90.24 ±0.08 
LS2 -17.3 ±0.24 340.23 ±0.63 90.37 ±0.11 
LS3 -16.5 ±0.41 375.18 ±0.48 90.58 ±0.31 
LS4 -15.4 ±0.09 400.25 ±0.51 90.74 ±0.52 
Mean ± SD, N= 
  
Fig 1: SEM of Tolnaftate liposomes of batch LS4 
 
 
 
Fig-2: Entrapment efficiency of different Tolnaftate liposomes formulations  
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Fig-3: Vesicle size of different Tolnaftate liposomes formulations 
 
 
Fig-2: In-vitro drug release profile of Tolnaftate liposomes 
 
RESULTS AND DISCUSSION: 
 
SEM image of Tolnaftate loaded liposomes (Batch LS4) is shown in Fig. 1. The image indicates 
that liposomes of spherical shape were formed bythe method employed to prepare them. 
Spherical and rod-shaped particles effectively adhere to cells. Hence, there is a greater 
probability for Tolnaftate loaded liposomes to adhere to cells.  
Vesicle size plays an important role with respect to permeation of liposomes through different 
membrane barriers. The vesicle size-range of all the Tolnaftate liposomes formulations was 
found to be 325.83 to 400.25 nm. It confirms the normal size distribution of the vesicles. The 
reproducibility of the liposomal formulation with respect to size was confirmed by preparing the 
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 formulations three times, but the statistical analysis was avoided asthe particle size data was 
highly reproducible each time. Higher vesicle size of Batch  LS4 of liposomes was observed, it 
may be due to partial aggregation. 
The % entrapment efficiency was found to be in the range of 90.24 -90.75 90.75 %. The % 
entrapment efficiency of optimized batch LS4 was found to be 90.74 %.  
Figure 2 shows in vitro drug release profile. The release characteristic could be attributed to the 
fact that Tolnaftate was trapped by the lipid, and therefore, Tolnaftate might get released 
gradually from the lipid vesicles. In a study of 10 hrs, maximum release  82.114% was shown by 
optimized batch LS4, while minimum 51.4 % drug release was shown by liposomes of batch 
LS3. It was observed that increase in the lipid concentration delaysthe drug release due to 
increased particle size and reduced surface area available for drug release. 
CONCLUSION: 
The present study has been a satisfactory attempt to formulate and evaluate liposome of 
Tolnaftate with a providing sustained delivery of drug. 
Ethanol (solvent) injection method was used to prepare liposome employing ethanol as solvents 
to dissolve the drug and the excipients. The prepared formulations were characterized for their 
particle size, morphology, drug entrapment, and in-vitro drug release studies. Almost all the 
formulations showed fairly acceptable values for all the parameters evaluated. The formulations 
showed good drug entrapment and in vitro released. The surfacemorphology of the prepared 
liposome was studied using scanning electron microscopy. From the SEM study it was conclude 
that prepared liposomes were spherical in shape. 
Based on different parameters like particle size, entrapment efficiency, drug release formulations 
of batch LS4 was selected as best formulation. 
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